Pharmacological Inhibition of Rab7A Sensitizes Bortezomib-Resistant Multiple Myeloma Cells by Disrupting Lysosomal Adaptation and Stem-Like Features

Objective Bortezomib resistance limits durable responses in multiple myeloma treatment. This study investigated whether pharmacological targeting of Rab7A with CID1067700 could disrupt lysosomal adaptation and resensitize bortezomib-resistant myeloma cells. Methods Dose–response profiles of bortezomib and CID1067700 were determined by MTT assay in bortezomib-sensitive RPMI 8226 and resistant RPMI 8226-7B cells. Combination effects were evaluated using Bliss independence and Highest Single Agent models. Lysosomal acidification and hydrolytic activity were assessed by flow cytometry, RAB7A protein levels by ELISA, and related gene expression by qPCR. CID1067700–RAB7A interactions were examined by molecular docking. RAB7A expression was also evaluated in bone marrow samples from patients with newly diagnosed multiple myeloma (NDMM), relapsed/refractory multiple myeloma (RRMM), and healthy controls. Results RPMI 8226-7B cells were 5.7-fold more resistant to bortezomib but showed no marked cross-resistance to CID1067700. Low-dose bortezomib increased CID1067700 sensitivity 1.2-fold in parental cells and 7.8-fold in resistant cells, with a maximum Bliss score of 47.93. Resistant cells exhibited higher basal lysosomal acidification and hydrolytic activity. CID1067700 reduced lysosomal acidification by approximately 25.3-fold at 48 h and suppressed the bortezomib-induced increase in hydrolytic activity. The combination increased the BAX/BCL2 ratio, while CID1067700 reduced BCRP/ABCG2, SOX2, OCT4, and NANOG expression in resistant cells. RAB7A expression was higher in RRMM samples. Conclusion Pharmacological Rab7 targeting disrupted lysosomal dependence and strongly resensitized bortezomib-resistant myeloma cells. Rab7A-regulated lysosomal homeostasis may represent a targetable vulnerability in bortezomib resistance.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11097077/v1
Primary Topic
Multiple Myeloma Research and Treatments
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Pharmacological Inhibition of Rab7A Sensitizes Bortezomib-Resistant Multiple Myeloma Cells by Disrupting Lysosomal Adaptation and Stem-Like Features

Tülin Özkan, Asuman Sunguroğlu, Meral Beksaç, Guluzar Gulnur Itez et al.
1 links
Research Square
Multiple Myeloma Research and Treatments
preprint

Pharmacological Inhibition of Rab7A Sensitizes Bortezomib-Resistant Multiple Myeloma Cells by Disrupting Lysosomal Adaptation and Stem-Like Features

Tülin Özkan, Asuman Sunguroğlu, Meral Beksaç, Guluzar Gulnur Itez, Doga Tezal Altindag, Kubra Gayret Aslan
preprint en

Abstract

Objective Bortezomib resistance limits durable responses in multiple myeloma treatment. This study investigated whether pharmacological targeting of Rab7A with CID1067700 could disrupt lysosomal adaptation and resensitize bortezomib-resistant myeloma cells. Methods Dose–response profiles of bortezomib and CID1067700 were determined by MTT assay in bortezomib-sensitive RPMI 8226 and resistant RPMI 8226-7B cells. Combination effects were evaluated using Bliss independence and Highest Single Agent models. Lysosomal acidification and hydrolytic activity were assessed by flow cytometry, RAB7A protein levels by ELISA, and related gene expression by qPCR. CID1067700–RAB7A interactions were examined by molecular docking. RAB7A expression was also evaluated in bone marrow samples from patients with newly diagnosed multiple myeloma (NDMM), relapsed/refractory multiple myeloma (RRMM), and healthy controls. Results RPMI 8226-7B cells were 5.7-fold more resistant to bortezomib but showed no marked cross-resistance to CID1067700. Low-dose bortezomib increased CID1067700 sensitivity 1.2-fold in parental cells and 7.8-fold in resistant cells, with a maximum Bliss score of 47.93. Resistant cells exhibited higher basal lysosomal acidification and hydrolytic activity. CID1067700 reduced lysosomal acidification by approximately 25.3-fold at 48 h and suppressed the bortezomib-induced increase in hydrolytic activity. The combination increased the BAX/BCL2 ratio, while CID1067700 reduced BCRP/ABCG2, SOX2, OCT4, and NANOG expression in resistant cells. RAB7A expression was higher in RRMM samples. Conclusion Pharmacological Rab7 targeting disrupted lysosomal dependence and strongly resensitized bortezomib-resistant myeloma cells. Rab7A-regulated lysosomal homeostasis may represent a targetable vulnerability in bortezomib resistance.

Research Square
Ankara University (TR), Istinye University (TR)
Good health and well-being
Multiple Myeloma Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon